ライフサイエンスコーパス: residual tumor

1 herapy followed by surgical resection of the residual tumor.

2 pathologic complete response, whereas 14 had residual tumor.

3 uld not be confirmed by iMRI, which detected residual tumor.

4 tients had undergone primary surgery with no residual tumor.

5 Postop plasma may stimulate the growth of residual tumor.

6 ucleated at 21 weeks of age and examined for residual tumor.

7 hemotherapy, and 93 were observed with gross residual tumor.

8 Eight patients had no evidence of residual tumor.

9 subsequent laparotomy revealed small-volume residual tumor.

10 ment session; this finding was indicative of residual tumor.

11 lay a role in the elimination of microscopic residual tumor.

12 y tumors demonstrating small areas of viable residual tumor.

13 wed no (T0) or only non-muscle-invasive (T1) residual tumor.

14 section cavity boundary was not specific for residual tumor.

15 respectively) (P < .001) in the depiction of residual tumor.

16 dissections, four of which were positive for residual tumor.

17 instances, this was associated with obvious residual tumor.

18 rfere with the detection of small amounts of residual tumor.

19 y (100% in this cohort) for detecting viable residual tumor.

20 Thirteen (23%) of 56 women had no residual tumor.

21 eeks after treatment revealed no evidence of residual tumor.

22 ironment that enhances growth of microscopic residual tumor.

23 tion RHC in A-NET, a quarter of patients had residual tumor.

24 xamination of the resection cavity walls for residual tumor.

25 n time groups overall or among patients with residual tumor.

26 of delaying resection, even in patients with residual tumor.

27 ed early (within 4 months) repeat of NSS for residual tumor.

28 ative for residual tumor versus positive for residual tumor.

29 hoice between eradication versus regrowth of residual tumors.

30 duce the negative effect of tissue repair on residual tumors.

31 esent a novel approach toward eradication of residual tumors.

32 ventional histological analysis in detecting residual tumors.

33 ich may contribute to collagen deposition in residual tumors.

34 After BCG, 66 specimens were TO and 32 had residual tumors.

35 a may be useful agent in retarding growth of residual tumors.

36 utic opportunities to target immune cells in residual tumors.

37 wing Her2 downregulation and remains high in residual tumors.

38 s immune cell infiltration in regressing and residual tumors.

39 ed RD3 loss in surviving resistant cells and residual tumors.

40 re (LNRS)-LNRS 1, complete response; 2, <10% residual tumor; 3, 10%-50% residual tumor; 4, >50% resid

41 response; 2, <10% residual tumor; 3, 10%-50% residual tumor; 4, >50% residual tumor; and 5, no respon

42 ucibility after subtraction of the estimated residual tumor activity from the first (18)F-FLT injecti

43 For patients with localized, gross residual tumor, adding doxorubicin (DOX) to the combinat

44 rease in CD4+ and CD8+ T-cell numbers at the residual tumor after androgen ablation.

45 ect was measured by pathologic assessment of residual tumor after anti-PD1 therapy.

46 Conclusion Intraoperative assessment for residual tumor after BCT using isMRI demonstrated promis

47 The fifth patient has residual tumor after cisplatin, etoposide, and bleomycin

48 igh positive predictive value for predicting residual tumor after excisional biopsy.

49 erapy (seven with pathologic IBC, three with residual tumor after mastectomy).

50 For detection of residual tumor after polypectomy, endorectal US had a se

51 nical course, and in 2 patients PET detected residual tumor after presumably complete tumor resection

52 otherapy (HIPEC) is to eradicate microscopic residual tumor after radical surgical tumor excision in

53 Assessment of residual tumor after resection of cerebral gliomas can b

54 y effects, and 11 scans for the detection of residual tumor after resection were obtained.

55 and l-[methyl-(3)H]-methionine ((3)H-MET) in residual tumor after surgery and possible false-positive

56 Assessment of residual tumor after surgery by amino acid PET seems to

57 , T3b/T4 disease, or greater than 1.5 cm3 of residual tumor after surgery.

58 /or radiotherapy, and only two of the 10 had residual tumor after surgery.

59 The residual tumor after treatment in tumors that were initi

60 like cells (CSC) are selectively enriched in residual tumors after anticancer therapies, which may ac

61 sistent gene expression pattern was found in residual tumors after docetaxel treatment.

62 Children with no residual tumors after induction therapy and no metastati

63 cantly increased survival in mouse models of residual-tumor after macrometastasis resection, perivasc

64 Residual tumor AGT activity, present 18 h after BG doses

65 e were evaluated by tumor-to-brain ratios in residual tumor and by maximum lesion-to-brain ratios nea

66 The aim was to determine site of residual tumor and its prognostic impact.

67 fluorescent molecules, we are able to detect residual tumor and metastases as small as 200 microm, wh

68 mary central nervous system lymphoma without residual tumor and pituitary tumors were reported recent

69 with HBV-related HCC and aided in monitoring residual tumor and recurrence clonality after tumor rese

70 tment efficacy on the basis of the extent of residual tumor and regressive changes within tumor tissu

71 ed in patients without a large postoperative residual tumor and without RT treatment delays.

72 would elicit an immune response directed at residual tumor and would reduce the incidence of recurre

73 splatin-resistant CD133(+)/CXCR4(+) cells in residual tumors and their metastatization.

74 stoma multiforme), as well as age, amount of residual tumor, and tumor location.

75 f nonapoptotic cells by approximately 70% in residual tumors, and enhanced the fraction of apoptotic

76 al tumor; 3, 10%-50% residual tumor; 4, >50% residual tumor; and 5, no response.

77 tive of response to anti-PD1 therapies while residual tumors are immune suppressed at end-of-treatmen

78 The viable residual tumor area was outlined and the measurement of

79 We have reported Area of Residual Tumor (ART) as a useful pathological assessment

80 , simple grading system based on the area of residual tumor (ART).

81 ove diagnostic accuracy for the detection of residual tumor as compared with MRI alone and would assi

82 line-filled surgical cavity was assessed for residual tumor at 3-T isMRI in the operating suite.

83 Irradiation was used only for residual tumor at consolidation or for progressive/recur

84 a T2 tumor but who was found to have a small residual tumor at mammography and US performed at the ti

85 Patients with less than 1 cm(3) residual tumor at mastectomy received an additional five

86 ely infiltrative properties of GBM result in residual tumor at neurosurgical resection margins, repre

87 ic accuracy of isMRI findings in identifying residual tumor at resection margins was assessed using h

88 nts for at least 1 year, with no evidence of residual tumor at serial CA-125 analysis or subsequent l

89 before surgery in patients with significant residual tumor at surgery (p = 0.0001).

90 In nonresponding patients, the risk of residual tumor at surgery was 100% (vs. 45% in responder

91 AC before surgery was strongly predictive of residual tumor at surgery, but its absence was less pred

92 therapy (24 Gy) in patients with significant residual tumor at surgery.

93 resection EGD, but seven of the 17 (41%) had residual tumor at surgery.

94 crease in (18)F-FDG uptake at 2 cycles means residual tumor at the end of NAC and a high risk of earl

95 re, when post-operative pathology identifies residual tumor at the surgical margins, re-excision surg

96 Among 18 patients with residual tumor at the time of vaccination, 4 (22%) had t

97 TEN loss were associated with more extensive residual tumors at RP.

98 or-resection procedures in order to identify residual tumors at the margins and to guide their comple

99 For patients with M0 tumors, residual tumor bulk (not extent of resection) is a predi

100 small number of patients (5 cases) with high residual tumor burden and dismal outcome; nevertheless,

101 che" that promotes the survival of a minimal residual tumor burden and serves as a reservoir for even

102 Residual tumor burden following treatment of ALK or ROS1

103 st cancer therapy response, as determined by residual tumor burden on pathology, were evaluated.

104 e plasma ctDNA post-surgery likely indicates residual tumor burden, studies have been performed to qu

105 Eyes were analyzed at 16 weeks of age for residual tumor burden, which was measured by gauging the

106 xenografts correlated inversely with visible residual tumor burden.

107 of residual tumor, versus > or = 1.5 cm2 of residual tumor by scan, were significantly different (P

108 nts, but for solid tumors they often leave a residual tumor-cell population.

109 to be seeded by dormant, therapy-refractory residual tumor cells (RTCs).

110 or cell-autonomous mechanisms of dormancy in residual tumor cells (RTCs).

111 des I to IV based on the percentage of vital residual tumor cells (VRTCs).

112 are important for clearing small numbers of residual tumor cells after chemotherapy-mediated cytored

113 Whereas patients with residual tumor cells after neoadjuvant therapy primarily

114 ight represent a novel approach to eliminate residual tumor cells after surgery and increase the effe

115 infection enhances the invasive capacity of residual tumor cells after surgery, thus facilitating th

116 ell transplantations (ASCTs) might eradicate residual tumor cells and decrease relapse rates.

117 geon to delineate tumor margins, to identify residual tumor cells and micrometastases, and to determi

118 h signaling in tumor recurrence from dormant residual tumor cells and provide evidence that dormancy

119 ast cancer, we identify interactions between residual tumor cells and their microenvironment as criti

120 can lead to tumor progression suggests that residual tumor cells are, in fact, quiescent and, theref

121 e to deliver anti-cancer agents which target residual tumor cells by bypassing the blood-brain barrie

122 tem cells in the resection cavity eradicated residual tumor cells by inducing caspase-mediated apopto

123 This latency suggests that a population of residual tumor cells can survive treatment and persist i

124 or these diseases but is often undermined by residual tumor cells contaminating the graft.

125 a more invasive and aggressive phenotype in residual tumor cells following chemotherapy.

126 The survival and recurrence of residual tumor cells following therapy constitutes one o

127 n (interquartile range [IQR]) percentages of residual tumor cells for optimal morphologic response wa

128 nation was thus associated with clearance of residual tumor cells from blood and long-term disease-fr

129 The MARI node contained residual tumor cells in 65 of these 95 patients.

130 ed on the extent of regressional changes and residual tumor cells in the resection specimen.

131 nical remission, implying that at least some residual tumor cells pass through a dormant phase prior

132 tion and p-STAT3[Y705] activation within the residual tumor cells surviving the initial antitumor res

133 To define early molecular changes within residual tumor cells that persist after treatment, we an

134 ing remains activated in a subset of dormant residual tumor cells that persist following HER2/neu dow

135 cell lung cancer (NSCLC) to characterize the residual tumor cells that survive chemotherapy treatment

136 breast cancer, and Par-4 is downregulated in residual tumor cells that survive neoadjuvant chemothera

137 urrent tumors that arise from a reservoir of residual tumor cells that survive therapy.

138 ft-versus-leukemia (GVL) effect to eradicate residual tumor cells through immunologic mechanisms.

139 With RECIST, the median (IQR) percentages of residual tumor cells were for partial response 30% (10%-

140 (>/=TRG2) and in 63 of these patients (89%), residual tumor cells were seen in the mucosa and/or subm

141 EM treatment results in metabolic changes in residual tumor cells, leading to the resistance to T cel

142 /T-LBL xenograft models, we also reveal that residual tumor cells, which remain present after short-t

143 gen itself, either injected or released from residual tumor cells, would boost the antibody response.

144 cted at baseline, indicating the presence of residual tumor cells.

145 sue that complicates the complete removal of residual tumor cells.

146 well as deregulation of lipid metabolism in residual tumor cells.

147 TM)-dependent DNA repair in oncogene-matched residual tumor cells.

148 effects that go beyond the direct killing of residual tumor cells.

149 Residual tumor commonly extended in or restricted to the

150 ytotoxic CD8(+) T-cell infiltration into the residual tumor compared with either treatment alone.

151 Analysis of sections of residual tumor confirmed replication of MV within the tu

152 In addition, residual tumors contained less CD133+ cancer cells follo

153 ations were categorized according to whether residual tumor could be definitely identified or exclude

154 T (grade >2) and adaptively escalated to the residual tumor defined on midtreatment FDG-PET up to a t

155 lete response, and nine had </= 0.2 cm(3) of residual tumor (defined as a near-complete response), wi

156 at we analyzed, all but 3 had no evidence of residual tumor (defined as negative surgical margins) fo

157 confirmed conjunctival SCC in all cases with residual tumor demonstrating scleral invasion (n = 15) a

158 Residual tumor did not correlate with tumor size (P = 0.

159 ototype handheld imaging device can identify residual tumor during intraoperative molecular imaging.

160 patients who had advanced ovarian cancer and residual tumor exceeding 1 cm in diameter after primary

161 g a role of adaptive immunity in controlling residual tumor foci.

162 the role of salvage CR in patients who have residual tumor following CR, a phase III randomized tria

163 pathologic response by determining extent of residual tumor following CRT (P0, 0% residual; P1, 1%-50

164 evel, was associated with drug resistance in residual tumors following combination treatment.

165 ve (FRalpha+) tumor areas at baseline and in residual tumors following neoadjuvant chemotherapy.

166 who had no surgical or clinical evidence of residual tumor for 1 year.

167 Twenty-nine specimens contained sufficient residual tumor for inclusion in a tissue microarray.

168 uced at comparison of pre- and posttreatment residual tumor for women with pPR (n = 4) (P = .033).

169 boost of 14.4 Gy was delivered to the gross residual tumor, for a total dose of 36 Gy.

170 ing cellular tumor, distinguish recurrent or residual tumor from posttreatment changes, and predict O

171 Notably, residual tumors from an unselected group of BC patients

172 complete tumor necrosis is uncommon, and the residual tumor generally rapidly recurs.

173 fer with hematopoietic stem cells suppresses residual tumor growth (graft-versus-tumor [GVT]) in canc

174 Cur and Apa (GS-CT-CA) delayed postoperative residual tumor growth in intraperitoneal and subcutaneou

175 itate liver regeneration) may play a role in residual tumor growth.

176 the resection cavity and delay postoperative residual tumor growth.

177 8.1%), partial LN response (LNRS 1-3 >=1 LN, residual tumor >=1 LN; n = 155, 20.3%), poor/no LN respo

178 tively); 64 patients (32.8%) had macroscopic residual tumor (>3 mm, pR2).

179 0 tumors, > or = 3 years with < or = 1.5 cm2 residual tumor, had a 78%+/-6% 5-year PFS rate.

180 ent during surgery, unknown primaries, or no residual tumor identified during surgery after a diagnos

181 supine) and may help clinicians evaluate for residual tumor immediately after BCS.

182 (prone) to surgery (supine) and to evaluate residual tumor immediately after breast-conserving surge

183 m-enhanced MR imaging correctly demonstrated residual tumor in 20 of 23 patients.

184 Axillary lymph node examination revealed residual tumor in 33% of patients who received 8 x CVAP

185 ive mortality rate was 4.2% with evidence of residual tumor in 34.6% of specimens.

186 AB alone did not detect surgically confirmed residual tumor in 37 of 208 women [FNR, 17.8%; 95% confi

187 , 89%) and CA-125 values, which demonstrated residual tumor in 44 patients (sensitivity, 65%; specifi

188 compared with laparotomy, which demonstrated residual tumor in 60 patients (sensitivity, 88%; specifi

189 Gadolinium-enhanced MR imaging depicted residual tumor in 61 patients (sensitivity, 90%; specifi

190 ablation by decreasing the tumor volume and residual tumor in an experimental carcinoma model.

191 d as complete LN response (LNRS 1 >=1 LN, no residual tumor in any LN; n = 62, 8.1%), partial LN resp

192 cystectomy, mass on cross-sectional imaging, residual tumor in explant >2 cm, tumor grade and perineu

193 should be followed by surgical resection of residual tumor in nonseminomatous GCT.

194 1311 in the ablation of a thyroid remnant or residual tumor in patients with differentiated thyroid c

195 Both surgical specimens revealed residual tumor in regions that were not in direct commun

196 CAIX-expressing tumors and the assessment of residual tumor in resection margins or metastatic lesion

197 High rates of residual tumor in the adventitial region even inside the

198 dical hysterectomy or confirm the absence of residual tumor in the cervix after a cone biopsy with ne

199 argins, 71.4% of ABBI and 70.4% of WL bx had residual tumor in the definitive treatment specimen.

200 ot a reliable criterion for the detection of residual tumor in the prostate after cryosurgical ablati

201 Twenty-five percent of the patients with residual tumor in the resected surgical specimen were lo

202 ase-free survival rate for the patients with residual tumor in the surgical specimen were 12.9 months

203 ced spoiled gradient-echo MR imaging depicts residual tumor in women with treated ovarian cancer, wit

204 ectiveness in reducing tumor number, the few residual tumors in mice treated with the combined drugs

205 Increased growth of residual tumors in the proximity of acute surgical wound

206 Residual tumors in the two arms showed comparable levels

207 nsitive in screening for trace quantities of residual tumors in various organs of SCID mice, and it c

208 tumor regression grade (TRG) 3-4 (>10% vital residual tumor) in qualitative and quantitative analyses

209 mal microenvironment, chemotherapy-resistant residual tumors inhabit a softer niche.

210 The ability to detect residual tumor intraoperatively resulted in a radiologic

211 T is relevant in cases where reoperation for residual tumor is considered.

212 s whether adjuvant chemotherapy is needed if residual tumor is found at surgery.

213 R were clinical N2 or N3 disease, pathologic residual tumor larger than 2 cm, a multifocal pattern of

214 Advanced nodal involvement at diagnosis, residual tumor larger than 2 cm, multifocal residual dis

215 ation necrosis with limited recurrent and/or residual tumor (less than 20% of resected tissue) in 16

216 mplete response or minimal residual disease (residual tumor <= 5 mm).

217 Complete resections, defined as a residual tumor <=0.175 cm3, were achieved in 90 patients

218 d residual DCIS only, 20 (54.1%) had minimal residual tumor (<5 mm), and 19 of 25 (76.0%) exhibited i

219 elative to the control xenograft tumors, the residual tumors manifested reduced expression of cell pr

220 continuation of treatment in the presence of residual tumor mass almost inevitably leads to tumor pro

221 n patients with stage III ovarian cancer and residual tumor masses of 2 cm or less.

222 plication of GCV (10 mg per kg) for 6 d, the residual tumor masses were excised and the animals chall

223 eve disease stabilization in the presence of residual tumor masses.

224 ilization, however, often in the presence of residual tumor masses.

225 but early postoperative MRI for detection of residual tumor may be misleading because of MRI signal c

226 inically unsuspected multifocal or extensive residual tumor may lend support for mastectomy rather th

227 The residual tumor measured a mean basal diameter of 10.6 mm

228 In the metastatic setting, residual tumor metabolic activity after the initiation o

229 pared with preoperative values in either the residual tumor (n = 5) or areas remote from the tumor on

230 x) samples (n = 629, p < 0.0001) and post-Tx residual tumors (n = 782, p < 0.0001).

231 esent images from human surgery which detect residual tumor not evident with state-of-the-art vFI.

232 Residual tumors obtained from angiostatin- and endostati

233 A postoperative residual tumor of more than 1.5 cm(2) was the strongest

234 ic strategy in selected patients who have no residual tumor on a repeat vigorous resection of the pri

235 tal vein encasement (HR 3.3; P = 0.007), and residual tumor on explant (HR 9.8; P < 0.001).

236 on final pathology (excluding those with no residual tumor on final pathology), 2/82 (2.4%) recurred

237 Adult patients with residual tumor on magnetic resonance imaging scan follow

238 dy were 45 years or older and had measurable residual tumor on postoperative MRI scans.

239 Patients with residual tumor on posttreatment biopsy were treated with

240 = .001, respectively), absence of bilateral residual tumor (P = .002 and P = .017, respectively), an

241 patients with complete tumor resection with residual tumor (P =.03).

242 oints; ypN3a to 3b = 3 points; less than 10% residual tumor per tumor bed = 1 point; 10% to 50% resid

243 al tumor per tumor bed = 1 point; 10% to 50% residual tumor per tumor bed = 2 points; and greater tha

244 r tumor bed = 2 points; and greater than 50% residual tumor per tumor bed = 3 points.

245 or distant disease: two stage 2A with gross residual tumor postsurgery, 11 stage 2B with ipsilateral

246 ients (67.2%) had no or microscopic (<=3 mm) residual tumor (pR0 or pR1, respectively); 64 patients (

247 at the primary tumor as defined by extent of residual tumor predicted overall survival (3 years: P0,

248 Boost radiotherapy to gross residual tumor present at the end of induction did not s

249 Sixty-eight women had residual tumor proved at laparotomy and biopsy or at cli

250 he gallbladder, (stage II/III) with no local residual tumor (R0) or microscopic residual tumor (R1).

251 no local residual tumor (R0) or microscopic residual tumor (R1).

252 Multivariate analysis demonstrated that residual tumor (R1, 2; p = 0.026) and CD31 low expressio

253 The positive margin rates and residual tumor rates are comparable between the ABBI and

254 6), subretinal fluid (P=0.035), thickness of residual tumor scar (P<0.001), and elevation of residual

255 idual tumor scar (P<0.001), and elevation of residual tumor scar (P<0.001).

256 In eyes with residual tumor showing scleral invasion or intraocular i

257 ed clinical management because an additional residual tumor site was identified.

258 sion, intraparenchymal liver metastasis, and residual tumor size were significant prognostic variable

259 ed s.c. FaDu xenograft tumors (i.e., reduced residual tumor size, enhanced apoptotic cell fraction, a

260 nd mammography have all been used to predict residual tumor size, there have been conflicting reports

261 Upon isolation from the tumor, the residual tumor-specific T cells were functionally tolera

262 a expression was the only factor, other than residual tumor status, to be an independent prognostic b

263 nclusion: The high specificity for detecting residual tumor suggests that supplementary (18)F-FET PET

264 uniformly in advanced tumors, highlighting a residual tumor-suppressive function conferred by the rem

265 e SUV(max) was less than 10.0 or the interim residual tumor SUV(max) was greater than 5.0, the Menton

266 In seven patients, MR imaging depicted residual tumor that was not found at laparotomy but was

267 eliver a continuous lethal radiation dose to residual tumors that are radiosensitized by PARP inhibit

268 )-l-tyrosine ((18)F-FET) is useful to detect residual tumor tissue after glioma resection.

269 Identification and removal of micro-scale residual tumor tissue during brain tumor surgery are key

270 hin tumors, thus facilitating the removal of residual tumor tissue during surgical procedures.

271 Complete removal of residual tumor tissue during surgical resection improves

272 he sensitivity of (18)F-FDG PET/CT to detect residual tumor tissue was 92% (95% confidence interval [

273 Histological analysis of residual tumor tissues revealed an almost complete absen

274 lization of tumor margins and elimination of residual tumor tissues.

275 correlated with diminished MYC expression in residual tumor tissues.

276 Fourteen operable patients with residual tumor underwent immediate cystectomy.

277 Four animals showing no residual tumor underwent PET 3 d after surgery to examin

278 en the patients who had a score negative for residual tumor versus positive for residual tumor.

279 nts with M0 tumors with less than 1.5 cm2 of residual tumor, versus > or = 1.5 cm2 of residual tumor

280 r observation indicated normalization of the residual tumor vessels, which was also implied by low le

281 therapy (EBRT) was necessary in 33 eyes with residual tumor, vitreous seeds, or both.

282 <0.0001, analysis of covariance (ANCOVA)] in residual tumor volume [0.26; 95% confidence interval (95

283 rescence image analysis routines to quantify residual tumor volume and viability.

284 A residual tumor volume below 20% of the pretreatment volu

285 ast-enhancing residual disease, as any other residual tumor volume is a negative predictor for PFS an

286 Initial and residual tumor volumes were measured on intraoperative T

287 with all reference assessments and no large residual tumor was 82% +/- 2% at 5 years.

288 The residual tumor was composed only of premalignant epithel

289 ents with positive results, the diagnosis of residual tumor was confirmed at biopsy or by clinical fo

290 Residual tumor was detected after RF thermal ablation in

291 Residual tumor was incorrectly predicted with MR imaging

292 l extension beyond the gross mucosal edge of residual tumor was observed in only 2 patients (1.8%), b

293 No evidence of residual tumor was seen on MR images obtained after the

294 Molecular characterization of the residual tumors was consistent with the induction of mac

295 Those with more than 1 cm(3) residual tumor were randomly assigned to receive an addi

296 ppearance in 40% of the animals, wherein the residual tumors were smaller in size with limited or no

297 ients with clinically suspected recurrent or residual tumors were studied with PET using Met as well

298 ) were downregulated in treatment responsive residual tumors, when compared with controls.

299 cantly induced the survivin protein level in residual tumors, whereas addition of PCat-siSurvivin com

300 Forty-four percent of these patients had residual tumor within axillary lymph nodes.